Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01482767
First received: November 28, 2011
Last updated: April 5, 2016
Last verified: April 2016
  Purpose
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.

Condition Intervention Phase
HIV Infections
Hepatitis C
Drug: Pegylated-Interferon Alfa 2b (PEG-IFN)
Drug: Ribavirin (RBV)
Drug: Boceprevir (BOC)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) [ Time Frame: 24 weeks after treatment discontinuation ] [ Designated as safety issue: No ]
    SVR24 was defined as undetectable HCV RNA (below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0) at 24 weeks after treatment discontinuation. Participants without HCV RNA for SVR24 determination were considered not to have achieved SVR24.


Secondary Outcome Measures:
  • Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) [ Time Frame: From study treatment dispensation to Week 72 ] [ Designated as safety issue: Yes ]
    Number of participants who experienced an AE (sign or symptom or laboratory abnormality) of Grade 3 or higher at any time after baseline while on study. The AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening.

  • Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) [ Time Frame: 12 weeks after treatment discontinuation ] [ Designated as safety issue: No ]
    SVR12 was defined as undetectable HCV RNA (below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0) at 12 weeks after treatment discontinuation. Participants without HCV RNA for SVR12 determination were considered not to have achieved SVR12.

  • Percentage of Participants With HIV-1 Viral Load <50 Copies/mL [ Time Frame: Entry and weeks (W) 4, 8, 12, 24, 28, 40, 48, 52, 60, 72 ] [ Designated as safety issue: No ]
    HIV-1 RNA testing was performed with Abbott RealTime HIV-1 assay (LLOQ=40 copies/mL) or with Roche COBAS AmpliPrep/Taqman HIV-1 assay (LLOQ=20 copies/mL).

  • CD4+ T-Cell Count (CD4) Change From Baseline [ Time Frame: Entry and weeks (W) 8, 12, 24, 28, 40, 48, 52, 60, 72 ] [ Designated as safety issue: No ]
    Change in CD4 T-cell count was calculated as value at the post entry visit minus the value at entry.

  • Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits [ Time Frame: Weeks (W) 4, 8, 12 ] [ Designated as safety issue: No ]
    Undetectable HCV RNA was defined as below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0.

  • Number of Participants With Undetectable HCV RNA at Week 16, 20, 24 and 28 Study Visits [ Time Frame: Weeks (W) 16, 20, 24, and 28 ] [ Designated as safety issue: No ]
    Undetectable HCV RNA was defined as below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0. This outcome measure was intended for a potential interim analysis when study data up to Week 28 were complete. However, this interim analysis was not conducted.

  • Number of Participants With Grade 2 or Higher Signs and Symptoms and Laboratory Abnormalities and Other Serious AEs [ Time Frame: From study treatment dispensation to Week 28 ] [ Designated as safety issue: Yes ]
    This outcome measure was intended for a potential interim analysis when study data up to Week 28 were complete. However, this interim analysis was not conducted. Refer to Outcome Measure 2 above for the safety outcome that includes the whole study duration from entry to week 72.


Enrollment: 262
Study Start Date: April 2012
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HCV Treatment-Naive (Group A)
Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
Drug: Pegylated-Interferon Alfa 2b (PEG-IFN)
1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Drug: Ribavirin (RBV)
800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Drug: Boceprevir (BOC)
800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
Experimental: HCV Treatment-Experienced (Group B)
Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
Drug: Pegylated-Interferon Alfa 2b (PEG-IFN)
1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Drug: Ribavirin (RBV)
800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Drug: Boceprevir (BOC)
800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Groups A and B):

  • Men and women 18 years of age or older
  • Presence of chronic HCV infection, defined by presence of plasma or serum HCV RNA in a participant with HCV antibody for at least 180 days, two documented HCV RNA positive results greater than 180 days apart, or positive HCV RNA with biopsy demonstrating chronic hepatitis. More information on this criterion can be found in the protocol.
  • Serum or plasma HCV RNA level 10,000 IU/mL or greater obtained within 42 days prior to study entry.
  • Screening HCV genotype 1 performed within 6 months prior to study entry.
  • Liver biopsy or HCV FibroSURE™ test within 104 weeks prior to study entry with interpretation consistent with chronic HCV infection. If a liver biopsy HCV FibroSURE™ test had not been performed within 104 weeks prior to study entry, then either a biopsy or HCV FibroSURE™ test must have been obtained prior to enrollment. The cut-off value for the FibroSURE™ test was 0.74, where greater than 0.74 was interpreted as cirrhosis. More information on this criterion can be found in the protocol.
  • Alpha feto protein (AFP) levels less than 50. If 50 or greater, they must have had a liver imaging study (e.g., ultrasound, computed tomography [CT] scan, magnetic resonance imaging [MRI] showing no evidence of hepatocellular carcinoma.
  • HIV-1 infection. More information on this criterion can be found in the protocol.
  • Currently not on any antiretroviral therapy (ART) for at least 4 weeks immediately prior to entry or on stable ART for at least 8 weeks prior to study entry using a dual NRTI backbone PLUS one of the following: EFV, RAL, LPV/RTV 400/100 mg twice daily, ATV/RTV, DRV/RTV 600/100 mg twice daily. Breaks in therapy for a maximum of 14 days were allowed. Dose modifications or changes in drugs during the 8 weeks prior to study entry were permitted unless the change in drug was due to treatment failure. More information on this criterion can be found in the protocol.
  • CD4+ T-cell count greater than 200 cells/mm^3 obtained within 42 days prior to study entry.
  • For participants on ART, screening plasma HIV-1 RNA less than 50 copies/mL obtained within 42 days prior to study entry. For participants not on ART, plasma HIV-1 RNA less than 50,000 copies/mL obtained within 42 days prior to study entry.
  • The following laboratory values within 42 days prior to entry:

    • Absolute neutrophil count (ANC) 1000/mm^3 or greater,
    • Hemoglobin greater than 12 g/dL for men and greater than 11 g/dL for women,
    • Platelet count greater than 80,000 per mm^3,
    • Creatinine less than 1.5 mg/dL,
    • Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase (ALT)/serum glutamic pyruvic transaminaseless (SGPT) less than or equal to 10 x the upper limit of normal (ULN),
    • Direct bilirubin less than 1.5 mg/dL,
    • International normalized ratio (INR) less than 1.5,
    • Serum lipase less than or equal to 1.5 x ULN,
    • Thyroid stimulating hormone (TSH) within normal range, unless accompanied by thyroid profile consistent with normal thyroid function.
  • For female participants of reproductive potential, a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL performed within 42 days prior to study entry. More information on this criterion can be found in the protocol.
  • All participants must have agreed not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
  • When participating in sexual activity that could lead to pregnancy, participants must have agreed to use at least two reliable methods of contraception simultaneously while receiving protocol-specified medications, and for 6 months after stopping the medications. Such methods include:

    • Condoms (male or female) with a spermicidal agent,
    • Diaphragm or cervical cap with spermicide,
    • Intrauterine device (IUD),
    • Tubal ligation.

More information on this criterion can be found in the protocol.

  • Participants not of reproductive potential were eligible without requiring the use of contraceptives. More information on this criterion can be found in the protocol.
  • Ability and willingness of participant to provide written informed consent.

Exclusion Criteria (Groups A and B):

  • Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.
  • Evidence of decompensated liver disease manifested by the presence of or history of ascites, variceal bleeding, or hepatic encephalopathy. If hepatic cirrhosis was determined by liver biopsy (Stage 4 Metavir or Stage 5, 6 Ishak) or by imaging, then participants had to be no more than Child-Pugh Class A and have a Child-Pugh-Turcotte (CPT) score of 6 or less. More information on this criterion can be found in the protocol.
  • Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency.
  • Infection with any HCV genotype other than genotype 1, or mixed genotype infection.
  • Uncontrolled or active depression or other psychiatric disorder such as untreated. Grade 3 psychiatric disorder or Grade 3 disorder not amenable to medical intervention that in the opinion of the site investigator might have precluded tolerability or safety of study requirements. Individuals with suicidal ideation or history of a suicidal attempt in the last 5 years prior to enrollment were excluded.
  • History of uncontrolled seizure disorders.
  • Serious illness including malignancy, active coronary artery disease within 24 weeks prior to study entry, or other chronic medical conditions that in the opinion of the site investigator may have precluded completion of the protocol.
  • Presence of active or acute AIDS-defining opportunistic infections within 12 weeks prior to study entry. More information on this criterion can be found in the protocol.
  • History of hemoglobinopathy (e.g., thalassemia) or any other cause of or tendency to hemolysis.
  • History of major organ transplantation with an existing functional graft.
  • History of autoimmune processes including Crohn's disease, ulcerative colitis, severe psoriasis, or rheumatoid arthritis that may be exacerbated by IFN use.
  • Breastfeeding.
  • Male participants with pregnant sexual partner.
  • Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days prior to study entry.
  • Use of systemic corticosteroids, lovastatin, simvastatin, interferon gamma, tumor necrosis factor(TNF)-alpha inhibitors, rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir or hydroxyurea within 14 days prior to study entry.
  • Previous use of any HCV protease or polymerase inhibitor.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would have interfered with adherence to study requirements.
  • Serious illness requiring systemic treatment and/or hospitalization within 42 days prior to entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01482767

  Hide Study Locations
Locations
United States, Alabama
Alabama CRS
Birmingham, Alabama, United States, 35294
United States, California
University of Southern California CRS
Los Angeles, California, United States, 90033-1079
UCLA CARE Center CRS
Los Angeles, California, United States, 90035
Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California, United States, 94304-5350
UCSD Antiviral Research Center CRS
San Diego, California, United States, 92103
Ucsf Hiv/Aids Crs
San Francisco, California, United States, 94110
Harbor-UCLA CRS
Torrance, California, United States, 90502
United States, Colorado
University of Colorado Hospital CRS
Aurora, Colorado, United States, 80045
Denver Public Health CRS
Denver, Colorado, United States, 80204
United States, District of Columbia
Georgetown University CRS (GU CRS)
Washington, District of Columbia, United States, 20007
United States, Georgia
The Ponce de Leon Center CRS
Atlanta, Georgia, United States, 30308-2012
United States, Illinois
Northwestern University CRS
Chicago, Illinois, United States, 60611
Rush University CRS
Chicago, Illinois, United States, 60612
United States, Maryland
IHV Baltimore Treatment CRS
Baltimore, Maryland, United States, 21201
Johns Hopkins University CRS
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
Boston, Massachusetts, United States, 02115
Bmc Actg Crs
Boston, Massachusetts, United States, 02118
United States, Michigan
Wayne State Univ. CRS
Detroit, Michigan, United States, 48201
Henry Ford Hosp. CRS
Detroit, Michigan, United States, 48202
United States, Missouri
Washington University Therapeutics (WT) CRS
St. Louis, Missouri, United States, 63110-1010
United States, New Jersey
Cooper Univ. Hosp. CRS
Camden, New Jersey, United States, 08103
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey, United States, 07103
United States, New York
Bronx-Lebanon Hosp. Ctr. CRS
Bronx, New York, United States, 10457
Weill Cornell Chelsea CRS
New York, New York, United States, 10011
Columbia P&S CRS
New York, New York, United States, 10032-3732
Weill Cornell Uptown CRS
New York, New York, United States, 10065
University of Rochester Adult HIV Therapeutic Strategies Network CRS
Rochester, New York, United States, 14642
United States, North Carolina
Chapel Hill CRS
Chapel Hill, North Carolina, United States, 27599
Duke Univ. Med. Ctr. Adult CRS
Durham, North Carolina, United States, 27710
United States, Ohio
Cincinnati Clinical Research Site
Cincinnati, Ohio, United States, 45219
MetroHealth CRS
Cleveland, Ohio, United States, 44109
Case Clinical Research Site
Cleveland, Ohio, United States, 44106
Ohio State University CRS
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Penn Therapeutics, CRS
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
Providence, Rhode Island, United States, 02906
United States, Tennessee
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, United States, 37204
United States, Texas
Trinity Health and Wellness Center CRS
Dallas, Texas, United States, 75208
Houston AIDS Research Team CRS
Houston, Texas, United States, 77030
United States, Virginia
Virginia Commonwealth University CRS
Richmond, Virginia, United States, 23298
United States, Washington
University of Washington AIDS CRS
Seattle, Washington, United States, 98104-9929
Puerto Rico
Puerto Rico AIDS Clinical Trials Unit CRS
San Juan, Puerto Rico, 00935
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Study Chair: Adeel A Butt, MD, MS University of Pittsburgh
Study Chair: Kenneth E Sherman, MD, PhD University of Cincinnati CRS
  More Information

Publications:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01482767     History of Changes
Other Study ID Numbers: A5294 (BIRTH)  11774  ACTG 5294  BIRTH 
Study First Received: November 28, 2011
Results First Received: April 5, 2016
Last Updated: April 5, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 24, 2016